c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma

• Váldodahkkit: Antonin Bouroumeau (Dahkki), Lucile Bussot (Dahkki), Thierry Bonnefoix (Dahkki), Cyril Fournier (Dahkki), Caroline Chapusot (Dahkki), Olivier Casasnovas (Dahkki), Laurent Martin (Dahkki), Anne McLeer (Dahkki), Edwige Col (Dahkki), Laurence David‐Boudet (Dahkki), Christine Lefebvre (Dahkki), Caroline Algrin (Dahkki), Tatiana Raskovalova (Dahkki), Marie‐Christine Jacob (Dahkki), Claire Vettier (Dahkki), Simon Chevalier (Dahkki), Mary B Callanan (Dahkki), Rémy Gressin (Dahkki), Anouk Emadali (Dahkki), Hervé Sartelet (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Diffuse large B‐cell lymphoma (DLBCL) is a clinically heterogeneous entity, in which the first‐line treatment currently consists of an immuno‐chemotherapy regimen (R‐CHOP). However, around 30% of patients will not respond or will relapse. Overexpression of c‐MYC or p53 is frequently found i...